Altimmune Dirección

Dirección controles de criterios 2/4

El CEO de Altimmune's es Vipin Garg , nombrado en Nov 2018, tiene una permanencia de 5.42 años. compensación anual total es $5.48M, compuesta por 11.3% salario y 88.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.41% de las acciones de la empresa, por valor de €1.93M. La antigüedad media del equipo directivo y de la junta directiva es de 3.5 años y 5.5 años, respectivamente.

Información clave

Vipin Garg

Chief Executive Officer (CEO)

US$5.5m

Compensación total

Porcentaje del salario del CEO	11.3%
Permanencia del CEO	5.5yrs
Participación del CEO	0.4%
Permanencia media de la dirección	3.6yrs
Promedio de permanencia en la Junta Directiva	5.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Vipin Garg en comparación con los beneficios de Altimmune?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$93m
Dec 31 2023	US$5m	US$620k	-US$88m
Sep 30 2023	n/a	n/a	-US$78m
Jun 30 2023	n/a	n/a	-US$81m
Mar 31 2023	n/a	n/a	-US$85m
Dec 31 2022	US$3m	US$580k	-US$85m
Sep 30 2022	n/a	n/a	-US$87m
Jun 30 2022	n/a	n/a	-US$97m
Mar 31 2022	n/a	n/a	-US$102m
Dec 31 2021	US$3m	US$566k	-US$97m
Sep 30 2021	n/a	n/a	-US$84m
Jun 30 2021	n/a	n/a	-US$68m
Mar 31 2021	n/a	n/a	-US$60m
Dec 31 2020	US$1m	US$514k	-US$49m
Sep 30 2020	n/a	n/a	-US$43m
Jun 30 2020	n/a	n/a	-US$36m
Mar 31 2020	n/a	n/a	-US$22m
Dec 31 2019	US$815k	US$500k	-US$21m
Sep 30 2019	n/a	n/a	-US$42m
Jun 30 2019	n/a	n/a	-US$34m
Mar 31 2019	n/a	n/a	-US$40m
Dec 31 2018	US$2m	US$44k	-US$42m

Compensación vs. Mercado: La compensación total de Vipin($USD5.48M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.02M).

Compensación vs. Ingresos: La compensación de Vipin ha aumentado mientras la empresa no es rentable.

CEO

Vipin Garg (65 yo)

5.5yrs

Permanencia

US$5,482,089

Compensación

Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Vipin Garg	President	5.5yrs	US$5.48m	0.41% $ 2.0m
Matthew Harris	Chief Medical Officer	4.8yrs	US$2.24m	0.076% $ 359.4k
Raymond Jordt	Chief Business Officer	1.3yrs	US$2.94m	0.019% $ 92.1k
Richard Eisenstadt	Chief Financial Officer	2.4yrs	US$619.69k	0.063% $ 301.7k
Bertrand Georges	Chief Technology Officer	7yrs	sin datos	sin datos
M. Roberts	Chief Scientific Officer	11.4yrs	US$1.41m	0.060% $ 286.0k
Tony Blandin	Vice President of Quality & Compliance Management	2.3yrs	sin datos	sin datos
Andrew Shutterly	Corporate Controller	1.3yrs	sin datos	sin datos

3.6yrs

Permanencia media

65yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 3G0 se considera experimentado (3.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Vipin Garg	President	5.5yrs	US$5.48m	0.41% $ 2.0m
Mitchel Sayare	Independent Chairman	14.1yrs	US$119.68k	0.037% $ 176.7k
John Gill	Independent Director	19.8yrs	US$103.68k	0.0039% $ 18.6k
David Drutz	Independent Director	7yrs	US$109.68k	0.042% $ 199.6k
Philip Hodges	Independent Director	7yrs	US$115.68k	0.037% $ 178.1k
Klaus Schafer	Independent Director	7yrs	US$104.68k	0.013% $ 61.5k
Wayne Pisano	Independent Director	5.8yrs	US$108.68k	0.012% $ 57.0k
Diane Jorkasky	Independent Director	4yrs	US$95.68k	0% $ 0
Rohit Loomba	Member of Mash Scientific Advisory Board	1.8yrs	sin datos	sin datos
Stephen A. Harrison	Member of Mash Scientific Advisory Board	1.8yrs	sin datos	sin datos
Michael Charlton	Member of Mash Scientific Advisory Board	1.8yrs	sin datos	sin datos
Mazen Noureddin	Member of Mash Scientific Advisory Board	1.8yrs	sin datos	sin datos

5.6yrs

Permanencia media

71yo

Promedio de edad

Junta con experiencia: La junta directiva de 3G0 se considera experimentada (5.5 años de antigüedad promedio).

Altimmune Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Altimmune, Inc., Annual General Meeting, Sep 28, 2023

Altimmune, Inc. Appoints Raymond Jordt as Chief Business Officer

Altimmune, Inc., Annual General Meeting, Sep 29, 2022

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)

Pomerantz LLP Announces Filing of Class Action Against Altimmune, Inc. and Certain Officers

Altimmune, Inc. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings released: US$1.66 loss per share (vs US$1.81 loss in FY 2022)

New major risk - Revenue and earnings growth

Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023

Altimmune, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Altimmune, Inc. Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

Third quarter 2023 earnings released: US$0.39 loss per share (vs US$0.48 loss in 3Q 2022)

Altimmune, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Altimmune, Inc. Grants Fast Track Designation by FDA for Pemvidutide for the Treatment of Non Alcoholic Steatohepatitis (Nash)

Altimmune, Inc., Annual General Meeting, Sep 28, 2023

Altimmune, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Altimmune, Inc. Announces Initiation of Phase 2b Impact Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Al Alcoholic Steatohepatitis

Altimmune, Inc. to Report Q1, 2023 Results on May 11, 2023

Altimmune, Inc. Appoints Raymond Jordt as Chief Business Officer

Altimmune, Inc. Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease

Third quarter 2022 earnings released: US$0.48 loss per share (vs US$0.81 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.48 loss per share (vs US$0.81 loss in 3Q 2021)

Altimmune, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Altimmune, Inc. Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

Altimmune, Inc. Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD

Altimmune, Inc., Annual General Meeting, Sep 29, 2022

Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.60 loss in 2Q 2021)

Altimmune, Inc. to Report Q2, 2022 Results on Aug 11, 2022

First quarter 2022 earnings released: US$0.44 loss per share (vs US$0.38 loss in 1Q 2021)

Altimmune, Inc. to Report Q1, 2022 Results on May 12, 2022

Insufficient new directors

Altimmune Announces Initiation of 48-Week Phase 2 Momentum Trial of Pemvidutide in Obesity

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity

Insufficient new directors

Insufficient new directors

Third quarter 2021 earnings released: US$0.81 loss per share (vs US$0.54 loss in 3Q 2020)

Altimmune Announces Positive Results from 12-Week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers

Altimmune, Inc. Reports an Impairment on Construction-In-Progress for the Three Months Ended June 30, 2021

Second quarter 2021 earnings released: US$0.60 loss per share (vs US$0.94 loss in 2Q 2020)

Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial

Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers

Forecast breakeven pushed back to 2024

Altimmune, Inc. Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID™

First quarter 2021 earnings released: US$0.38 loss per share (vs US$0.26 loss in 1Q 2020)

Forecast breakeven pushed back to 2025

Altimmune Announces New Preclinical Data for AdCOVID™ Demonstrating Sterilizing Immunity After a Single Intranasal Dose

Altimmune, Inc. Announces Additional Preclinical Data for Its Single Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID

Full year 2020 earnings released: US$1.91 loss per share (vs US$1.60 loss in FY 2019)

Revenue beats expectations

Altimmune, Inc. Commences Enrollment in Phase 1 Clinical Trial of AdCOVID- A Needle-Free, Single-Dose Intranasal Covid-19 Vaccine Candidate

Altimmune, Inc. to Report Fiscal Year 2020 Results on Feb 25, 2021

Altimmune, Inc. Announces FDA Clearance of AdCOVID™ IND Application

New 90-day high: €17.57

New 90-day high: €12.28

Altimmune, Inc. Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B

Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial

Altimmune Announces Submission of Investigational New Drug Application To the U.S. Food and Drug Administration to Commence A Phase 1 Clinical Study of Its Single-Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID

Third quarter 2020 earnings released: US$0.54 loss per share

Revenue beats expectations

Altimmune, Inc. Adds Lonza as a Manufacturing Partner for Supply of AdCOVID its Single-Dose Intranasal Vaccine Candidate for COVID-19

New 90-day low: €7.08

Altimmune, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: €9.42

Altimmune and UAB Announces Publication of Compelling Pre-clinical Data for AdCOVID™ Intranasal COVID-19 Vaccine Candidate

First half earnings released

Altimmune, Inc. to Report Q2, 2020 Results on Aug 12, 2020

Altimmune, Inc. has completed a Follow-on Equity Offering in the amount of $114.99837 million.

Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Microcap Value Index

Análisis de compensación del CEO

CEO